Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synvisc-One
- Development stage
- Unknown
- Lead developer
- Sanofi
- Administration
- Intraarticular
01
Overview
Synvisc-One (hylan G-F 20) is an elastoviscous high molecular weight fluid containing hylan A and hylan B polymers, which are chemically cross-linked derivatives of hyaluronan (sodium hyaluronate). It functions as a biologic viscosupplement, acting as a lubricant and shock absorber in the synovial fluid of joints to alleviate pain associated with osteoarthritis. Developed by Genzyme (a Sanofi company), Synvisc-One is administered as a single intra-articular injection. While it is widely approved for the treatment of pain in osteoarthritis of the knee, it has also been evaluated in pivotal clinical trials for the treatment of primary osteoarthritis of the hip.
- Brand names
- Synvisc-One
- Other names
- hylan G-F 20Synvisc One
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Synvisc-One.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synvisc-One.